Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.

<h4>Background</h4>Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously report...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mélanie Bézard, Silvia Oghina, Damien Vitiello, Mounira Kharoubi, Ekaterini Kordeli, Arnault Galat, Amira Zaroui, Soulef Guendouz, Floriane Gilles, Jason Shourick, David Hamon, Vincent Audard, Emmanuel Teiger, Elsa Poullot, Valérie Molinier-Frenkel, François Lemonnier, Onnik Agbulut, Fabien Le Bras, Thibaud Damy
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/bbbf2a9e4d304b4583602af0c7c9d90b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bbbf2a9e4d304b4583602af0c7c9d90b
record_format dspace
spelling oai:doaj.org-article:bbbf2a9e4d304b4583602af0c7c9d90b2021-12-02T20:06:16ZDexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.1932-620310.1371/journal.pone.0257189https://doaj.org/article/bbbf2a9e4d304b4583602af0c7c9d90b2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257189https://doaj.org/toc/1932-6203<h4>Background</h4>Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously reported that NT-ProBNP levels can double within 24h of dexamethasone administration, suggesting a deleterious impact on cardiac function. In this study, we evaluate the role of dexamethasone in early cardiovascular mortality during treatment.<h4>Methods and findings</h4>We retrospectively assessed 100 de novo cardiac AL patients (62% male, mean age 68 years) treated at our institute between 2009 and 2018 following three chemotherapy regimens: CyBorDComb (all initiated on day 1; 34 patients), DCyBorSeq (D, day 1; Cy, day 8; Bor, day 15; 17 patients), and CyBorDSeq (Cy, day 1; Bor, day 8; D, day 15; 49 patients). The primary endpoint was cardiovascular mortality and cardiac transplantation at days 22 and 455. At day 22, mortality was 20.6% with CyBorDComb, 23.5% with DCyBorSeq, and 0% with CyBorDSeq (p = 0.003). At day 455, mortality was not significantly different between regimens (p = 0.195). Acute toxicity of dexamethasone was evaluated on myocardial function using a rat model of isolated perfused heart. Administration of dexamethasone induced a decrease in left ventricular myocardium contractility and relaxation (p<0.05), supporting a potential negative inotropic effect of dexamethasone in AL-CA patients with severe cardiac involvement.<h4>Conclusion</h4>Delaying dexamethasone during the first chemotherapy cycle reduces the number of early deaths without extending survival. It is clear that dexamethasone is beneficial in the long-term treatment of patients with AL-CA. However, the initial introduction of dexamethasone during treatment is critical, but may be associated with early cardiac deaths in severe CA. Thus, it is important to consider the dosage and timing of dexamethasone introduction on a patient-severity basis. The impact of dexamethasone in the treatment of AL-CA needs further investigation.Mélanie BézardSilvia OghinaDamien VitielloMounira KharoubiEkaterini KordeliArnault GalatAmira ZarouiSoulef GuendouzFloriane GillesJason ShourickDavid HamonVincent AudardEmmanuel TeigerElsa PoullotValérie Molinier-FrenkelFrançois LemonnierOnnik AgbulutFabien Le BrasThibaud DamyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257189 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Mélanie Bézard
Silvia Oghina
Damien Vitiello
Mounira Kharoubi
Ekaterini Kordeli
Arnault Galat
Amira Zaroui
Soulef Guendouz
Floriane Gilles
Jason Shourick
David Hamon
Vincent Audard
Emmanuel Teiger
Elsa Poullot
Valérie Molinier-Frenkel
François Lemonnier
Onnik Agbulut
Fabien Le Bras
Thibaud Damy
Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
description <h4>Background</h4>Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously reported that NT-ProBNP levels can double within 24h of dexamethasone administration, suggesting a deleterious impact on cardiac function. In this study, we evaluate the role of dexamethasone in early cardiovascular mortality during treatment.<h4>Methods and findings</h4>We retrospectively assessed 100 de novo cardiac AL patients (62% male, mean age 68 years) treated at our institute between 2009 and 2018 following three chemotherapy regimens: CyBorDComb (all initiated on day 1; 34 patients), DCyBorSeq (D, day 1; Cy, day 8; Bor, day 15; 17 patients), and CyBorDSeq (Cy, day 1; Bor, day 8; D, day 15; 49 patients). The primary endpoint was cardiovascular mortality and cardiac transplantation at days 22 and 455. At day 22, mortality was 20.6% with CyBorDComb, 23.5% with DCyBorSeq, and 0% with CyBorDSeq (p = 0.003). At day 455, mortality was not significantly different between regimens (p = 0.195). Acute toxicity of dexamethasone was evaluated on myocardial function using a rat model of isolated perfused heart. Administration of dexamethasone induced a decrease in left ventricular myocardium contractility and relaxation (p<0.05), supporting a potential negative inotropic effect of dexamethasone in AL-CA patients with severe cardiac involvement.<h4>Conclusion</h4>Delaying dexamethasone during the first chemotherapy cycle reduces the number of early deaths without extending survival. It is clear that dexamethasone is beneficial in the long-term treatment of patients with AL-CA. However, the initial introduction of dexamethasone during treatment is critical, but may be associated with early cardiac deaths in severe CA. Thus, it is important to consider the dosage and timing of dexamethasone introduction on a patient-severity basis. The impact of dexamethasone in the treatment of AL-CA needs further investigation.
format article
author Mélanie Bézard
Silvia Oghina
Damien Vitiello
Mounira Kharoubi
Ekaterini Kordeli
Arnault Galat
Amira Zaroui
Soulef Guendouz
Floriane Gilles
Jason Shourick
David Hamon
Vincent Audard
Emmanuel Teiger
Elsa Poullot
Valérie Molinier-Frenkel
François Lemonnier
Onnik Agbulut
Fabien Le Bras
Thibaud Damy
author_facet Mélanie Bézard
Silvia Oghina
Damien Vitiello
Mounira Kharoubi
Ekaterini Kordeli
Arnault Galat
Amira Zaroui
Soulef Guendouz
Floriane Gilles
Jason Shourick
David Hamon
Vincent Audard
Emmanuel Teiger
Elsa Poullot
Valérie Molinier-Frenkel
François Lemonnier
Onnik Agbulut
Fabien Le Bras
Thibaud Damy
author_sort Mélanie Bézard
title Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
title_short Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
title_full Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
title_fullStr Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
title_full_unstemmed Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
title_sort dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/bbbf2a9e4d304b4583602af0c7c9d90b
work_keys_str_mv AT melaniebezard dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT silviaoghina dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT damienvitiello dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT mounirakharoubi dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT ekaterinikordeli dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT arnaultgalat dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT amirazaroui dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT soulefguendouz dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT florianegilles dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT jasonshourick dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT davidhamon dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT vincentaudard dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT emmanuelteiger dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT elsapoullot dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT valeriemolinierfrenkel dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT francoislemonnier dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT onnikagbulut dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT fabienlebras dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
AT thibauddamy dexamethasoneisassociatedwithearlydeathsinlightchainamyloidosispatientswithseverecardiacinvolvement
_version_ 1718375446685417472